Scientists test gentler drug regimen for risky cancer transplants

This study is testing whether using lower doses of a key drug (cyclophosphamide) and for a shorter time after a stem cell transplant can reduce side effects while still preventing a dangerous complication called graft-versus-host disease (GVHD). It involves people ages 15-65 with serious blood cancers who need a transplant from a half-matched family donor. The goal is to find a treatment plan that controls the cancer with fewer medication-related problems for the patient.